Navigation Links
Catalan researchers identify a key component of cell division
Date:8/21/2012

This press release is available in Spanish and in French

- The Nek9 protein is required for chromosomes to separate into two identical groups.

- Nek9 exerts its action between two molecules of interest for the pharmaceutical industry as anti-tumoral agents, and for which inhibitors are already in advanced stages of clinical trials. Nek9 could be added to the list of candidates.

A study by the Institute for Research in Biomedicine (IRB Barcelona) and the Center for Genomic Regulation (acronym in Catalan CRG) highlights the protein Nek9 as a decisive factor in cell division, a fundamental process for both the development of an organism and tissue maintenance. Headed by the researchers Joan Roig at IRB Barcelona and Isabelle Vernos at the CRG, the study describes that Nek9 is required for a cell to be able to divide the chromosomes into two identical groups in order to ensure efficient and accurate cell division. In fact, errors in the correct distribution of chromosomes cause many spontaneous miscarriages, some genetic defects such as trisomies, and are also related to the development of tumours.

"Through this study we demonstrate that a fourth family of proteins, namely NIMA and specifically Nek9, exert functions in cell division as important as those undertaken by the widely studied CDK (cdk1), Polo (Plk1) and Aurora (Aurora A and B) kinases", explains the scientist Joan Roig, specialist in the NIMA protein family and co-discoverer of Nek9.

The scientists study cell division and more specifically the first stages of mitosis or the process of the cell nucleus dividing in half. The distribution of the chromosomes requires the development of machinery that separates the two copies of the genetic material in such a way that the two resulting cells from the division inherit the same content. Nek9 participates in the preparation of the centrosomes, organelles involved in the organization of mitotic spindle development, a kind of "rugby ball" made up of microtubules or "molecular wiring", which, together with several "motors" pull and separate the chromosomes into two identical groups. The study reports that Nek9 modifies and controls NEDD1, the function of which was discovered in 2006 by Jens Luders, a researcher at IRB Barcelona, and a molecule involved in the formation of the new microtubules required to prepare the mitotic spindle. "Without Nek9 the spindle would not form properly and cell division would be hindered, the cells would die or cause aneuploidies, with unequal distribution of chromosomes, an event that is common in tumours", explains Isabelle Vernos, an expert in microtubules and cell division.

Interference with cell division is one of the main strategies used against cancer and the pharmaceutical industry is currently testing new drugs that inhibit Plk1, Aurora and Eg5. Nek9 falls between Plk1 and Eg5, the latter being a motor protein, whose function in mitosis Roig contributed to elucidate in a previous study. "We are doing double-edged work: we describe how proteins involved in the initial stages of cell division are related in time and space and in parallel we highlight the possible therapeutic tools, whether markers of disease or anti-mitotic agents, that can stop division and tumour growth", says Roig.

Conducted using eggs from the frog Xenopus laevis and human cells, the study is published today in Current Biology, one of the main journals devoted to basic biology.


'/>"/>
Contact: Sarah Sherwood
sarah.sherwood@irbbarcelona.org
34-934-034-636
Institute for Research in Biomedicine (IRB Barcelona)
Source:Eurekalert

Related medicine news :

1. Spirituality correlates to better mental health regardless of religion, say MU researchers
2. IU researchers interview pro-anorexic bloggers for groundbreaking new study
3. Researchers awarded National Cancer Institute grants aimed at answering provocative questions
4. Why are elderly duped? UI researchers explain why
5. Moffitt Cancer Center researchers validate molecular signature to predict radiation therapy benefit
6. By studying animal health, researchers find improved ways for developing, testing cancer therapies
7. Researchers aim to grow salivary glands using patients own cells
8. Moffitt Cancer Center researchers discover how cancer cells hijack a mechanism to grow
9. CNIO researchers discover a new therapy that prevents lung cancer growth in mice
10. BUSM researchers part of multi-center study on cardiac amyloidosis
11. BUSM/VA researchers uncover gender differences in the effects of long-term alcoholism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Farmingdale, NY (PRWEB) , ... March 27, 2017 ... ... specializing in epigenetic research products enables researchers to pursue the recent RNA methylation ... RNA methylation . In light of the newfound characteristics of N6-methyladenosine, or ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Association of Healthcare ... will hold their first Northeast Regional AHVAP Meeting. For 2017, Dr. Hayes will ... chain and value analysis professionals have a ‘seat at the table’ with clinical ...
(Date:3/27/2017)... ... ... According to the American Cancer Society , the average 15-year survival ... the cancer spreads to other organs, bones, or lymph nodes, however, the 5-year survival ... latter group, tune in to Lifestyle Magazine on April 9, 2017, to ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... Conventional sodium testing methods are complicated and require expert user knowledge. In a ... analytical method dedicated to the simplified, yet highly accurate, determination of sodium. , ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... agreement to resolve the pending litigation between itself and 1800 Vending DBA Healthy ... Utah). , “I am thrilled to announce that we have now reached a ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... and BOSTON , March 27, ... global pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of innovative therapies based upon tetracycline ... of sarecycline for the treatment of moderate to ... endpoints. Sarecycline is a once-daily, oral, narrow spectrum ...
(Date:3/27/2017)... Calif. , March 27, 2017  Impax Laboratories, ... has appointed Paul M. Bisaro as Impax,s ... the Company,s Board, effective March 27, 2017. Mr. Bisaro ... served as Interim President and Chief Executive Officer since ... of generic and branded pharmaceutical experience, Mr. Bisaro, 56, ...
(Date:3/27/2017)... -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing ... children, today reported financial results for the fourth ... and provided an update on its corporate activities. ... during the fourth quarter of 2016 through the ... study, and with our lead development candidate, PRX-OTC, ...
Breaking Medicine Technology: